22:30 , Apr 4, 2019 |  BC Extra  |  Preclinical News

Nimbus exposes complete ACLY structure, discovers allosteric inhibitory sites

Nimbus is spinning out a subsidiary to develop ACLY inhibitors targeting a new allosteric site on the enzyme that it discovered in collaboration with Schrödinger and Columbia University. BioCentury identified lipid biosynthesis regulator ACLY as...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
17:36 , Mar 8, 2019 |  BC Week In Review  |  Company News

Esperion submits NDAs to FDA for LDL-C lowering products, EMA starts review

Esperion said it submitted two NDAs to FDA for bempedoic acid (ETC-1002) and a bempedoic acid/ezetimibe combination tablet to treat elevated LDL-C in patients who need additional LDL-C lowering despite the use of currently accessible...
17:30 , Jan 11, 2019 |  BC Week In Review  |  Company News

Daiichi to market Esperion's LDL-C lowering products in Europe

Esperion Therapeutics Inc. (NASDAQ:ESPR) will get $150 million cash up front in exchange for granting the European subsidiary of Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive rights to commercialize bempedoic acid (ETC-1002) and bempedoic acid/ezetimibe in...
20:03 , Jan 4, 2019 |  BC Extra  |  Company News

Daiichi to market Esperion's LDL-C lowering products in Europe

Esperion Therapeutics Inc. (NASDAQ:ESPR) will get $150 million cash up front in exchange for granting the European subsidiary of Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive rights to commercialize bempedoic acid (ETC-1002) and bempedoic acid/ezetimibe in...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Esperion hypercholesterolemia candidate meets in fifth and final Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) as monotherapy met the primary endpoint of reducing LDL-C in the Phase III CLEAR Wisdom (1002-047) trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients...
18:51 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Esperion combo lowers LDL-C in Phase III for high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
19:45 , Aug 27, 2018 |  BC Extra  |  Clinical News

Esperion combo lowers LDL-C in high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
15:29 , May 25, 2018 |  BC Week In Review  |  Clinical News

Esperion's hypercholesterolemia candidate meets in Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily 180 mg oral bempedoic acid (ETC-1002) met the primary endpoint of reducing LDL-C from baseline to week 12 vs. placebo (23% vs. 1%, p<0.001) in the Phase III CLEAR...